CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
Permanent trial closure for MAC4 (IBCSG 24-02): A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer and MAC5 (IBCSG 25-02): A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
The new BLC6 MODERN phase II/III clinical trial will investigate the role of circulating tumour DNA (ctDNA) in the blood to see if it is an effective guide for what type of immunotherapy is most effective. Researchers want to understand whether a blood test can more effectively determine who should get immunotherapy after surgery for bladder cancer and which immunotherapy treatment is best.
In early November, our CCTG Patient Representative Committee Chair, Judy Needham was invited to Brussels, Belgium, as a Breast International Group (BIG) Patient Partner. During her visit she attended BIG Executive Board Meetings, Patient Partner Meetings, and was privileged to be invited to a luncheon with the Queen Mathilde of Belgium who is the honorary President of BIG.
With sadness CCTG acknowledges the passing of one of our influential international research partners, Mr Russell Conley. Russell was Chief Executive Officer of the Australasian Gastro-Intestinal Trials Group (AGITG) and the GI Cancer Institute for 22 years. He was instrumental in all of the growing list of CCTG and AGITG GI collaborations, including CO.17, CO.20, CO.23, CO.29, NE.2 as well as the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs).
